IQV
IQVIA Holdings Inc.
Price Chart
Latest Quote
$185.62
+14.34 (+8.37%)
Current Price
| Previous Close | $171.28 |
| Open | $174.69 |
| Day High | $187.79 |
| Day Low | $175.32 |
| Volume | 1,813,381 |
Stock Information
| Shares Outstanding | 166.90M |
| Total Debt | $16.22B |
| Cash Equivalents | $2.10B |
| Revenue | $16.63B |
| Net Income | $1.38B |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $31.12B |
| P/E Ratio | 23.13 |
| EPS (TTM) | $8.06 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $45.22B |
| Sales | $16.63B |
| Income | $1.38B |
| Book/sh | $37.27 |
| Cash/sh | $12.60 |
| Employees | 93K |
Financial Ratios
| Quick Ratio | 0.66 |
| Current Ratio | 0.75 |
| Debt/Eq | 255.43 |
| EPS Growth TTM | 10.00% |
Returns & Margins
| ROA | 5.13% |
| ROE | 22.49% |
| Gross Margin | 32.99% |
| Operating Margin | 13.61% |
| Profit Margin | 8.33% |
Ownership
| Insider Ownership | 1.08% |
| Institutional Ownership | 104.25% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.13 |
| PEG | 0.75 |
| P/S | 1.87 |
| P/B | 5.00 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $225.47 |
Technical Indicators
| SMA20 | $180.25 |
| SMA50 | $173.81 |
| SMA200 | $195.15 |
| RSI | 49.51 |
| ATR | 6.9850 |
| Shares Float | 158.55M |
| Short Float | 3.40% |
| Short Ratio | 2.53 |
| Volatility | 1.22 |
| Rel Volume | 0.75 |
Performance History
| Week | +9.23% |
| Month | +15.08% |
| Quarter | +12.55% |
| 6 Months | -16.91% |
| YTD | -17.28% |
| Year | +17.56% |
| 3 Years | -13.26% |
| 5 Years | -24.31% |
| 10 Years | +204.03% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $186.43 | 1,284,044 |
| 2026-06-24 | $185.62 | 1,862,400 |
| 2026-06-23 | $171.28 | 1,622,200 |
| 2026-06-22 | $167.81 | 2,136,100 |
| 2026-06-18 | $167.77 | 3,703,600 |
| 2026-06-17 | $170.67 | 1,859,400 |
| 2026-06-16 | $179.17 | 989,300 |
| 2026-06-15 | $178.39 | 1,732,200 |
| 2026-06-12 | $181.46 | 1,254,300 |
| 2026-06-11 | $181.06 | 1,605,500 |
| 2026-06-10 | $182.17 | 1,209,900 |
| 2026-06-09 | $186.25 | 1,311,100 |
| 2026-06-08 | $183.69 | 1,203,600 |
| 2026-06-05 | $183.45 | 1,279,000 |
| 2026-06-04 | $186.88 | 1,676,300 |
| 2026-06-03 | $182.05 | 1,561,400 |
| 2026-06-02 | $180.64 | 1,679,300 |
| 2026-06-01 | $186.82 | 1,404,800 |
| 2026-05-29 | $182.21 | 2,597,500 |
| 2026-05-28 | $181.09 | 2,253,800 |
| 2026-05-27 | $165.62 | 1,400,300 |
| 2026-05-26 | $162.00 | 2,005,200 |
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
đ° Latest News
Does Slower Growth at IQVIA Holdings (IQV) Challenge Its Core DataâDriven Pharma Enablement Story?
Simply Wall St. âĸ 2026-06-24T02:09:53Z
1 Healthcare Stock with Impressive Fundamentals and 2 We Turn Down
StockStory âĸ 2026-06-23T08:40:46Z
1 of Wall Streetâs Favorite Stocks on Our Buy List and 2 We Turn Down
StockStory âĸ 2026-06-22T11:31:19Z
Morgan Stanley sees writing on wall for key drug research stocks
TheStreet âĸ 2026-06-19T02:03:00Z
Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-17T13:47:56Z
Morgan Stanley favors Charles River Over IQVIA in CRO sector reset
Investing.com âĸ 2026-06-17T13:13:21ZIQVIA (IQV): Buy, Sell, or Hold Post Q1 Earnings?
StockStory âĸ 2026-06-17T09:32:51Z
Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity
Zacks âĸ 2026-06-15T15:12:00Z
2 S&P 500 Stocks Worth Investigating and 1 Facing Headwinds
StockStory âĸ 2026-06-12T11:17:20Z
Q1 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment
StockStory âĸ 2026-06-09T19:26:14Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $10,880,000,000 | $10,030,000,000 | $9,745,000,000 | $9,382,000,000 |
| Cost Of Revenue | $10,880,000,000 | $10,030,000,000 | $9,745,000,000 | $9,382,000,000 |
| Total Revenue | $16,310,000,000 | $15,405,000,000 | $14,984,000,000 | $14,410,000,000 |
| Operating Revenue | $16,310,000,000 | $15,405,000,000 | $14,984,000,000 | $14,410,000,000 |
| Expenses | ||||
| Interest Expense | $729,000,000 | $670,000,000 | $672,000,000 | $416,000,000 |
| Total Expenses | $14,023,000,000 | $13,136,000,000 | $12,923,000,000 | $12,583,000,000 |
| Other Income Expense | $-12,000,000 | $23,000,000 | $34,000,000 | $-61,000,000 |
| Other Non Operating Income Expenses | $99,000,000 | $90,000,000 | $124,000,000 | $-33,000,000 |
| Net Non Operating Interest Income Expense | $-684,000,000 | $-623,000,000 | $-636,000,000 | $-403,000,000 |
| Interest Expense Non Operating | $729,000,000 | $670,000,000 | $672,000,000 | $416,000,000 |
| Operating Expense | $3,143,000,000 | $3,106,000,000 | $3,178,000,000 | $3,201,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,360,000,000 | $1,373,000,000 | $1,358,000,000 | $1,091,000,000 |
| Net Interest Income | $-684,000,000 | $-623,000,000 | $-636,000,000 | $-403,000,000 |
| Interest Income | $45,000,000 | $47,000,000 | $36,000,000 | $13,000,000 |
| Normalized Income | $1,453,462,000 | $1,427,940,000 | $1,441,790,000 | $1,113,652,000 |
| Net Income From Continuing And Discontinued Operation | $1,360,000,000 | $1,373,000,000 | $1,358,000,000 | $1,091,000,000 |
| Total Operating Income As Reported | $2,182,000,000 | $2,202,000,000 | $1,977,000,000 | $1,799,000,000 |
| Net Income Common Stockholders | $1,360,000,000 | $1,373,000,000 | $1,358,000,000 | $1,091,000,000 |
| Net Income | $1,360,000,000 | $1,373,000,000 | $1,358,000,000 | $1,091,000,000 |
| Net Income Including Noncontrolling Interests | $1,361,000,000 | $1,373,000,000 | $1,358,000,000 | $1,091,000,000 |
| Net Income Continuous Operations | $1,361,000,000 | $1,373,000,000 | $1,358,000,000 | $1,091,000,000 |
| Earnings From Equity Interest Net Of Tax | $22,000,000 | $5,000,000 | $0 | $-12,000,000 |
| Pretax Income | $1,591,000,000 | $1,669,000,000 | $1,459,000,000 | $1,363,000,000 |
| Special Income Charges | $-111,000,000 | $-67,000,000 | $-90,000,000 | $-28,000,000 |
| Interest Income Non Operating | $45,000,000 | $47,000,000 | $36,000,000 | $13,000,000 |
| Operating Income | $2,287,000,000 | $2,269,000,000 | $2,061,000,000 | $1,827,000,000 |
| Depreciation Amortization Depletion Income Statement | $1,144,000,000 | $1,114,000,000 | $1,125,000,000 | $1,130,000,000 |
| Depreciation And Amortization In Income Statement | $1,144,000,000 | $1,114,000,000 | $1,125,000,000 | $1,130,000,000 |
| Gross Profit | $5,430,000,000 | $5,375,000,000 | $5,239,000,000 | $5,028,000,000 |
| Per Share | ||||
| Diluted EPS | $7.84 | $7.49 | $7.29 | $5.72 |
| Basic EPS | $7.91 | $7.57 | $7.39 | $5.82 |
| Other | ||||
| Tax Effect Of Unusual Items | $-17,538,000 | $-12,060,000 | $-6,210,000 | $-5,348,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $3,575,000,000 | $3,520,000,000 | $3,346,000,000 | $2,937,000,000 |
| Total Unusual Items | $-111,000,000 | $-67,000,000 | $-90,000,000 | $-28,000,000 |
| Total Unusual Items Excluding Goodwill | $-111,000,000 | $-67,000,000 | $-90,000,000 | $-28,000,000 |
| Reconciled Depreciation | $1,144,000,000 | $1,114,000,000 | $1,125,000,000 | $1,130,000,000 |
| EBITDA (Bullshit earnings) | $3,464,000,000 | $3,453,000,000 | $3,256,000,000 | $2,909,000,000 |
| EBIT | $2,320,000,000 | $2,339,000,000 | $2,131,000,000 | $1,779,000,000 |
| Diluted Average Shares | $173,500,000 | $183,400,000 | $186,300,000 | $190,600,000 |
| Basic Average Shares | $171,900,000 | $181,300,000 | $183,800,000 | $187,600,000 |
| Diluted NI Availto Com Stockholders | $1,360,000,000 | $1,373,000,000 | $1,358,000,000 | $1,091,000,000 |
| Minority Interests | $-1,000,000 | $0 | $0 | $0 |
| Tax Provision | $252,000,000 | $301,000,000 | $101,000,000 | $260,000,000 |
| Other Special Charges | $6,000,000 | - | $6,000,000 | - |
| Restructuring And Mergern Acquisition | $105,000,000 | $67,000,000 | $84,000,000 | $28,000,000 |
| Selling General And Administration | $1,999,000,000 | $1,992,000,000 | $2,053,000,000 | $2,071,000,000 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-15,075,000,000 | $-13,142,000,000 | $-13,294,000,000 | $-12,976,000,000 |
| Total Assets | $29,944,000,000 | $26,899,000,000 | $26,681,000,000 | $25,337,000,000 |
| Total Non Current Assets | $23,695,000,000 | $21,070,000,000 | $21,085,000,000 | $20,356,000,000 |
| Other Non Current Assets | $505,000,000 | $520,000,000 | $455,000,000 | $472,000,000 |
| Non Current Deferred Assets | $357,000,000 | $194,000,000 | $166,000,000 | $118,000,000 |
| Non Current Deferred Taxes Assets | $357,000,000 | $194,000,000 | $166,000,000 | $118,000,000 |
| Investmentin Financial Assets | $108,000,000 | $108,000,000 | $105,000,000 | $68,000,000 |
| Goodwill And Other Intangible Assets | $21,578,000,000 | $19,209,000,000 | $19,406,000,000 | $18,741,000,000 |
| Other Intangible Assets | $4,962,000,000 | $4,499,000,000 | $4,839,000,000 | $4,820,000,000 |
| Current Assets | $6,249,000,000 | $5,829,000,000 | $5,596,000,000 | $4,981,000,000 |
| Other Current Assets | $519,000,000 | $592,000,000 | $546,000,000 | $561,000,000 |
| Prepaid Assets | $162,000,000 | $154,000,000 | $141,000,000 | $151,000,000 |
| Receivables | $3,427,000,000 | $3,240,000,000 | $3,413,000,000 | $2,960,000,000 |
| Receivables Adjustments Allowances | $-51,000,000 | $-42,000,000 | $-34,000,000 | $-36,000,000 |
| Other Receivables | $1,783,000,000 | $1,856,000,000 | $1,942,000,000 | $1,624,000,000 |
| Taxes Receivable | $27,000,000 | $36,000,000 | $32,000,000 | $43,000,000 |
| Accounts Receivable | $1,668,000,000 | $1,390,000,000 | $1,473,000,000 | $1,329,000,000 |
| Cash Cash Equivalents And Short Term Investments | $2,141,000,000 | $1,843,000,000 | $1,496,000,000 | $1,309,000,000 |
| Cash And Cash Equivalents | $1,980,000,000 | $1,702,000,000 | $1,376,000,000 | $1,216,000,000 |
| Cash Financial | $1,980,000,000 | $1,702,000,000 | $1,376,000,000 | $1,216,000,000 |
| Non Current Prepaid Assets | - | - | - | $472,000,000 |
| Debt | ||||
| Net Debt | $13,744,000,000 | $12,281,000,000 | $12,297,000,000 | $11,531,000,000 |
| Total Debt | $15,949,000,000 | $14,156,000,000 | $13,896,000,000 | $13,011,000,000 |
| Long Term Debt And Capital Lease Obligation | $14,109,000,000 | $13,011,000,000 | $13,178,000,000 | $12,859,000,000 |
| Long Term Debt | $13,884,000,000 | $12,838,000,000 | $12,955,000,000 | $12,595,000,000 |
| Current Debt And Capital Lease Obligation | $1,840,000,000 | $1,145,000,000 | $718,000,000 | $152,000,000 |
| Current Debt | $1,840,000,000 | $1,145,000,000 | $718,000,000 | $152,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $23,314,000,000 | $20,832,000,000 | $20,569,000,000 | $19,572,000,000 |
| Total Non Current Liabilities Net Minority Interest | $14,976,000,000 | $13,875,000,000 | $14,078,000,000 | $13,994,000,000 |
| Other Non Current Liabilities | $688,000,000 | $668,000,000 | $698,000,000 | $671,000,000 |
| Non Current Deferred Liabilities | $179,000,000 | $196,000,000 | $202,000,000 | $464,000,000 |
| Non Current Deferred Taxes Liabilities | $179,000,000 | $196,000,000 | $202,000,000 | $464,000,000 |
| Current Liabilities | $8,338,000,000 | $6,957,000,000 | $6,491,000,000 | $5,578,000,000 |
| Other Current Liabilities | $489,000,000 | $193,000,000 | $294,000,000 | $152,000,000 |
| Current Deferred Liabilities | $2,118,000,000 | $1,779,000,000 | $1,799,000,000 | $1,797,000,000 |
| Payables And Accrued Expenses | $2,990,000,000 | $2,935,000,000 | $2,712,000,000 | $2,497,000,000 |
| Interest Payable | $85,000,000 | $81,000,000 | $66,000,000 | $43,000,000 |
| Payables | $920,000,000 | $892,000,000 | $825,000,000 | $806,000,000 |
| Total Tax Payable | $140,000,000 | $156,000,000 | $116,000,000 | $161,000,000 |
| Income Tax Payable | $140,000,000 | $156,000,000 | $116,000,000 | $161,000,000 |
| Accounts Payable | $780,000,000 | $736,000,000 | $709,000,000 | $645,000,000 |
| Equity | ||||
| Common Stock Equity | $6,503,000,000 | $6,067,000,000 | $6,112,000,000 | $5,765,000,000 |
| Total Equity Gross Minority Interest | $6,630,000,000 | $6,067,000,000 | $6,112,000,000 | $5,765,000,000 |
| Stockholders Equity | $6,503,000,000 | $6,067,000,000 | $6,112,000,000 | $5,765,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-943,000,000 | $-1,038,000,000 | $-867,000,000 | $-727,000,000 |
| Other Equity Adjustments | $-943,000,000 | $-1,038,000,000 | $-867,000,000 | $-727,000,000 |
| Retained Earnings | $7,425,000,000 | $6,065,000,000 | $4,692,000,000 | $3,334,000,000 |
| Long Term Equity Investment | $324,000,000 | $266,000,000 | $134,000,000 | $94,000,000 |
| Other | ||||
| Treasury Shares Number | $89,500,000 | $82,100,000 | $75,700,000 | $70,700,000 |
| Ordinary Shares Number | $169,600,000 | $176,100,000 | $181,500,000 | $185,700,000 |
| Share Issued | $259,100,000 | $258,200,000 | $257,200,000 | $256,400,000 |
| Tangible Book Value | $-15,075,000,000 | $-13,142,000,000 | $-13,294,000,000 | $-12,976,000,000 |
| Invested Capital | $22,227,000,000 | $20,050,000,000 | $19,785,000,000 | $18,512,000,000 |
| Working Capital | $-2,089,000,000 | $-1,128,000,000 | $-895,000,000 | $-597,000,000 |
| Capital Lease Obligations | $225,000,000 | $173,000,000 | $223,000,000 | $264,000,000 |
| Total Capitalization | $20,387,000,000 | $18,905,000,000 | $19,067,000,000 | $18,360,000,000 |
| Minority Interest | $127,000,000 | $0 | - | $0 |
| Treasury Stock | $11,357,000,000 | $10,103,000,000 | $8,741,000,000 | $7,740,000,000 |
| Additional Paid In Capital | $11,375,000,000 | $11,140,000,000 | $11,025,000,000 | $10,895,000,000 |
| Capital Stock | $3,000,000 | $3,000,000 | $3,000,000 | $10,898,000,000 |
| Common Stock | $3,000,000 | $3,000,000 | $3,000,000 | $10,898,000,000 |
| Long Term Capital Lease Obligation | $225,000,000 | $173,000,000 | $223,000,000 | $264,000,000 |
| Current Deferred Revenue | $2,118,000,000 | $1,779,000,000 | $1,799,000,000 | $1,797,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $901,000,000 | $905,000,000 | $968,000,000 | $980,000,000 |
| Current Accrued Expenses | $2,070,000,000 | $2,043,000,000 | $1,887,000,000 | $1,691,000,000 |
| Investments And Advances | $432,000,000 | $374,000,000 | $239,000,000 | $162,000,000 |
| Goodwill | $16,616,000,000 | $14,710,000,000 | $14,567,000,000 | $13,921,000,000 |
| Net PPE | $823,000,000 | $773,000,000 | $819,000,000 | $863,000,000 |
| Accumulated Depreciation | $-905,000,000 | $-819,000,000 | $-803,000,000 | $-840,000,000 |
| Gross PPE | $1,728,000,000 | $1,592,000,000 | $1,622,000,000 | $1,703,000,000 |
| Other Properties | $1,193,000,000 | $1,078,000,000 | $1,099,000,000 | $1,183,000,000 |
| Machinery Furniture Equipment | $150,000,000 | $147,000,000 | $147,000,000 | $157,000,000 |
| Properties | $385,000,000 | $367,000,000 | $376,000,000 | $363,000,000 |
| Other Short Term Investments | $161,000,000 | $141,000,000 | $120,000,000 | $93,000,000 |
| Investmentsin Associatesat Cost | - | - | $134,000,000 | $94,000,000 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $2,051,000,000 | $2,114,000,000 | $1,500,000,000 | $1,586,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $2,654,000,000 | $2,716,000,000 | $2,149,000,000 | $2,260,000,000 |
| Cash Flow From Continuing Operating Activities | $2,654,000,000 | $2,716,000,000 | $2,149,000,000 | $2,260,000,000 |
| Operating Gains Losses | $-66,000,000 | $-27,000,000 | $-20,000,000 | $29,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-603,000,000 | $-602,000,000 | $-649,000,000 | $-674,000,000 |
| Investing Cash Flow | $-2,305,000,000 | $-1,444,000,000 | $-1,603,000,000 | $-2,006,000,000 |
| Cash Flow From Continuing Investing Activities | $-2,305,000,000 | $-1,444,000,000 | $-1,603,000,000 | $-2,006,000,000 |
| Net Other Investing Changes | $-1,000,000 | $2,000,000 | $5,000,000 | $8,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,244,000,000 | $-1,350,000,000 | $-992,000,000 | $-1,168,000,000 |
| Financing Cash Flow | $-150,000,000 | $-878,000,000 | $-382,000,000 | $-329,000,000 |
| Cash Flow From Continuing Financing Activities | $-150,000,000 | $-878,000,000 | $-382,000,000 | $-329,000,000 |
| Net Other Financing Charges | $-86,000,000 | $-17,000,000 | $-131,000,000 | $-31,000,000 |
| Net Common Stock Issuance | $-1,244,000,000 | $-1,350,000,000 | $-992,000,000 | $-1,168,000,000 |
| Other | ||||
| Repayment Of Debt | $-8,593,000,000 | $-1,132,000,000 | $-5,582,000,000 | $-2,659,000,000 |
| Issuance Of Debt | $9,840,000,000 | $1,685,000,000 | $6,384,000,000 | $3,600,000,000 |
| Interest Paid Supplemental Data | $647,000,000 | $589,000,000 | $556,000,000 | $379,000,000 |
| End Cash Position | $1,980,000,000 | $1,702,000,000 | $1,376,000,000 | $1,216,000,000 |
| Beginning Cash Position | $1,702,000,000 | $1,376,000,000 | $1,216,000,000 | $1,366,000,000 |
| Effect Of Exchange Rate Changes | $79,000,000 | $-68,000,000 | $-4,000,000 | $-75,000,000 |
| Changes In Cash | $199,000,000 | $394,000,000 | $164,000,000 | $-75,000,000 |
| Proceeds From Stock Option Exercised | $-67,000,000 | $-64,000,000 | $-61,000,000 | $-71,000,000 |
| Common Stock Payments | $-1,244,000,000 | $-1,350,000,000 | $-992,000,000 | $-1,168,000,000 |
| Net Issuance Payments Of Debt | $1,247,000,000 | $553,000,000 | $802,000,000 | $941,000,000 |
| Net Long Term Debt Issuance | $1,247,000,000 | $553,000,000 | $802,000,000 | $941,000,000 |
| Long Term Debt Payments | $-8,593,000,000 | $-1,132,000,000 | $-5,582,000,000 | $-2,659,000,000 |
| Long Term Debt Issuance | $9,840,000,000 | $1,685,000,000 | $6,384,000,000 | $3,600,000,000 |
| Net Investment Purchase And Sale | $-18,000,000 | $-2,000,000 | $-44,000,000 | $-5,000,000 |
| Sale Of Investment | $2,000,000 | - | - | $0 |
| Purchase Of Investment | $-20,000,000 | $-2,000,000 | $-44,000,000 | $-5,000,000 |
| Net Business Purchase And Sale | $-1,758,000,000 | $-867,000,000 | $-915,000,000 | $-1,335,000,000 |
| Purchase Of Business | $-1,758,000,000 | $-867,000,000 | $-915,000,000 | $-1,335,000,000 |
| Net PPE Purchase And Sale | $-528,000,000 | $-577,000,000 | $-649,000,000 | $-674,000,000 |
| Sale Of PPE | $75,000,000 | $25,000,000 | $0 | $0 |
| Purchase Of PPE | $-603,000,000 | $-602,000,000 | $-649,000,000 | $-674,000,000 |
| Change In Working Capital | $125,000,000 | $158,000,000 | $-280,000,000 | $-84,000,000 |
| Change In Other Working Capital | $242,000,000 | $9,000,000 | $-29,000,000 | $31,000,000 |
| Change In Payables And Accrued Expense | $-395,000,000 | $-40,000,000 | $103,000,000 | $299,000,000 |
| Change In Payable | $-395,000,000 | $-40,000,000 | $103,000,000 | $299,000,000 |
| Change In Account Payable | $-96,000,000 | $115,000,000 | $267,000,000 | $427,000,000 |
| Change In Tax Payable | $-299,000,000 | $-155,000,000 | $-164,000,000 | $-128,000,000 |
| Change In Income Tax Payable | $-299,000,000 | $-155,000,000 | $-164,000,000 | $-128,000,000 |
| Change In Prepaid Assets | $218,000,000 | $7,000,000 | $34,000,000 | $7,000,000 |
| Change In Receivables | $60,000,000 | $182,000,000 | $-388,000,000 | $-421,000,000 |
| Other Non Cash Items | $23,000,000 | $21,000,000 | $18,000,000 | $15,000,000 |
| Stock Based Compensation | $247,000,000 | $206,000,000 | $217,000,000 | $194,000,000 |
| Deferred Tax | $-180,000,000 | $-129,000,000 | $-269,000,000 | $-115,000,000 |
| Deferred Income Tax | $-180,000,000 | $-129,000,000 | $-269,000,000 | $-115,000,000 |
| Depreciation Amortization Depletion | $1,144,000,000 | $1,114,000,000 | $1,125,000,000 | $1,130,000,000 |
| Depreciation And Amortization | $1,144,000,000 | $1,114,000,000 | $1,125,000,000 | $1,130,000,000 |
| Amortization Cash Flow | $984,000,000 | $965,000,000 | $974,000,000 | $970,000,000 |
| Amortization Of Intangibles | $984,000,000 | $965,000,000 | $974,000,000 | $970,000,000 |
| Depreciation | $160,000,000 | $149,000,000 | $151,000,000 | $160,000,000 |
| Earnings Losses From Equity Investments | $-22,000,000 | $-5,000,000 | $0 | $12,000,000 |
| Gain Loss On Investment Securities | $-44,000,000 | $-22,000,000 | $-20,000,000 | $27,000,000 |
| Net Income From Continuing Operations | $1,361,000,000 | $1,373,000,000 | $1,358,000,000 | $1,091,000,000 |
| Income Tax Paid Supplemental Data | - | $295,000,000 | $340,000,000 | $255,000,000 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $-10,000,000 |
| Net Short Term Debt Issuance | - | - | $-325,000,000 | $325,000,000 |
| Short Term Debt Payments | - | - | $-2,709,000,000 | $-2,025,000,000 |
| Short Term Debt Issuance | - | - | $2,384,000,000 | $2,350,000,000 |
Fetched: 2026-06-23